1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014

Biosimilar and Biosuperior Therapeutic Antibodies 2014
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of March 2014.

Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.
The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.

2013 Sales data are provided for

- Rituxan/MabThera
- Arzerra
- Zevalin
- Gazyva
- Herceptin
- Perjeta
- Kadcyla
- Avastin
- Zaltrap
- Erbitux
- Vectibix
- Yervoy
- Adcetris
- Poteligeo
- Humira
- Enbrel
- Remicade
- Simponi
- Cimzia
- Orencia
- Nulojix
- Ilaris
- Arcalyst
- Tysabri
- Soliris
- Xolair
- Stelara
- Actemra/RoActemra
- Benlysta
- Lemtrada
- ReoPro
- Nplate
- Prolia
- Lucentis
- Eylea
- Synagis

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:

- CD20
- Her2
- CD52
- B7.1/B7.2 (CD80/CD86)
- IL-6R
- Alpha4/beta1/7 integrin
- IgE
- Complement C5
- IL-12/IL-23

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
Table of Contents
1. 2013 Sales of Recombinant Therapeutic Antibodies

- Overview and Summary of Antibody Sales 2013
- Cancer Antibody Sales 2013
- Inflammatory and Autoimmune Antibody Sales 2013
- Cardiohematometabolic Antibody Sales 2013
- Ophthalmic Antibody Sales 2013
- Antiviral Antiody Sales 2013

2. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors

- Marketed CD20 Antibodies and Sales

-           Rituxan/MabThera Pipeline and Sales

-           Arzerra Pipeline and Sales

-           Gazyva Pipeline and Sales

-           Bexxar and Zevalin Pipeline and Sales
- Biosuperior CD20 Antibodies
- Biosimilar CD20 Antibodies

-           Rituxan/MabThera (rituximab) Biosimilars

-           Arzerra (ofatumumab) Biosimilars

3. Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

- Marketed Her2 Antibodies

-           Herceptin Sales and Pipeline

-           Perjeta Sales and Pipeline

-           Kadcyla Sales and Pipeline
- Trastuzumab Biobetters/Biosuperiors

-           Engineered Her2 Antibodies

-           Bi- and Multispecific Her2 Antibodies

-           Her2 Antibody-Drug Conjugates

-           Her2 Imaging Antibodies
- Trastuzumab Biosimilars

4. VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
4a. Bevacizumab Biosimilars and Biosuperiors

- Marketed VEGF Antibodies

-           Avastin Sales and Pipeline

-           Zaltrap Sales and Pipeline
- andldquo;Next Generation Avastinandrdquo; Pipeline

-           Anti-VEGF Antibody Pipeline

-           Anti-VEGF-Receptor Antibody Pipeline

-           Bispecific Anti-VEGF Antibody Pipeline
- Avastin Biosimilar Pipeline

4b. Ranibizumab Biosimilars and Biosuperiors

- Marketed VEGF Antibody

-           Lucentis Sales and Pipeline

-           Eylea Sales and Pipeline
- andldquo;Next Generation Lucentisandrdquo; Pipeline
- Lucentis Biosimilar Pipeline

5. EGF-R Antibodies -Biosimilars and Biosuperiors

- Marketed EGF-R Antibodies

-           Erbitux Sales and Pipeline

-           Vectibix Sales and Pipeline

-           Nimotuzumab Pipeline
- EGF-R Antibody Biobetters/Biosuperiors

-           Engineered EGF-R Antibodies

-           Bi- and Multispecific EGF-R Antibodies

-           EGF-R Antibody-Drug Conjugates
- EGF-R Antibody Biosimilars

-           Cetuximab Biosimilars

-           Panitumumab Biosimilars

6. TNF Antibodies -Biosimilars and Biosuperiors

- Marketed TNF Antibodies

-           Humira Sales and Pipeline

-           Remicade Sales and Pipeline

-           Enbrel Sales and Pipeline

-           Simponi Sales and Pipeline

-           Cimzia Sales and Pipeline
- Biosuperior / Biobetter TNF Antibodies
- Biosimilar TNF Antibodies

-           Humira Biosimilar Antibody Pipeline

-           Remicade Biosimilar Antibody Pipeline

-           Enbrel Biosimilar Antibody Pipeline

-           Simponi Biosimilar Antibody Pipeline

-           Cimzia Biosimilar Antibody Pipeline

7. IgE Antibodies: Xolair, Biosuperiors and Biosimilars

Marketed IgE Antibody Sales and Pipeline

Biosuperior IgE Antibodies

Biosimilar IgE Antibodies
8. Interleukin-6 Receptor (IL-6R) Antibodies: Actemra, Biosuperiors and Biosimilars

Marketed Il-6R Antibody Sales and Pipeline

Biosuperior IL-6(R) Antibodies

Biosimilar IL-6(R) Antibodies
9. GPIIb/IIIa Antibodies: ReoPro, Biosuperios and Biosimilars

Marketed GPIIb/IIIa Antibody Sales and Pipeline

Biosimilar GPIIb/IIIa Antibodies
10. CD52 Antibodies: Lemtrada, Biosuperios and Biosimilars

Marketed CD52 Antibody Sales and Pipeline

Biosimilar CD52 Antibodies
11. Apha4/beta1/7 Antibodies: Tysabri, Biosuperiors and Biosimilars

Marketed Alpha4/beta1/7 Antibody Sales and Pipeline

Biosimilar Alpha4/beta1/7 Antibodies
12. Complement C5 Antibodies: Soliris, Biosuperiors and Biosimilars

Marketed C5 Antibody Sales and Pipeline

Biosuperior C5 Antibodies

Biosimilar C5 Antibodies
13. Respiratory Syncytial Virus (RSV): Synagis, Biosuperiors and Biosimilars

RSV Antibody Sales and Pipeline

Biosuperior RSV Antibodies

Biosimilar RSV Antibodies
14. RANKL Antibodies: Prolia/XGEVA, Biosuperiors and Biosimilars

Marketed RANKL Antibody Sales and Pipeline

Biosuperior RANKL Antibodies
15. CD80/86 (B7-1/B7-2) Antibodies: Orencia; Nulojix, Biosuperiors and Biosimilars

CD80/86 Antibody Sales and Pipeline

Biosuperior CD80/86 Antibodies

Biosimilar CD80/86 Antibodies
16. Interleukin-12/-23 Antibodies: Stelara, Biosuperiors and Biosimilars

Marketed IL-12/-23 Antibody Sales and Pipeline

Biosimilar IL-12/-23 Antibodies
17.  Corporate  Biosimilar and Biosuperior Therapeutic Antibody Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4 157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Global Biosimilars Industry

Global Biosimilars Industry

  • $ 4 500
  • Industry report
  • July 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts ...

Global Biosimilars And Follow-On Biologics Market Research Report 2016

Global Biosimilars And Follow-On Biologics Market Research Report 2016

  • $ 2 850
  • Industry report
  • September 2016
  • by 9Dimen Research

2016 Global Biosimilars And Follow-On Biologics Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Biosimilars And Follow-On Biologics ...

The Future Of Biosimilars 2016

July 2016 $ 2 360

Global Biosimilar Market Outlook 2022

September 2016 $ 1 500

Download Unlimited Documents from Trusted Public Sources

Biosimilar Market in the US

  • October 2016
    4 pages
  • Biosimilar  


    Clinical Trial  

  • United States  

View report >

Biosimilar Industry in the US

  • September 2016
    28 pages
  • Biosimilar  


  • United States  

View report >

Global Vaccine Industry

  • September 2016
    47 pages
  • Vaccine  



  • World  

View report >

Bioprocessing Industry

2 months ago

Biosimilar Statistics

2 months ago

Biosimilar Statistics

2 months ago

Related Market Segments :

Targeted Therapy


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.